We are live on ! Find out more
SLRN

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

109 hedge funds and large institutions have $613M invested in ACELYRIN in 2024 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 27

5.32% more ownership

Funds ownership: 88.02%93.35% (+5.3%)

1% less funds holding

Funds holding: 110109 (-1)

4% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 26

4% less capital invested

Capital invested by funds: $639M → $613M (-$25.9M)

17% less funds holding in top 10

Funds holding in top 10: 65 (-1)

29% less call options, than puts

Call options by funds: $4.79M | Put options by funds: $6.78M

Holders
109
Holders Change
-1
Holders Change %
-0.91%
% of All Funds
1.57%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.07%
New
25
Increased
46
Reduced
27
Closed
26
Calls
$4.79M
Puts
$6.78M
Net Calls
-$1.99M
Net Calls Change
-$6.43M
Name Holding Trade Value Shares
Change
Change in
Stake
VF
76
Virtu Financial
New York
$147K +$166K +21,834 New
T. Rowe Price Associates
77
T. Rowe Price Associates
Maryland
$140K +$157K +20,703 New
ProShare Advisors
78
ProShare Advisors
Maryland
$134K +$62.1K +8,176 +70%
AFP
79
Ausdal Financial Partners
Iowa
$130K -$7.6K -1,000 -5%
CUAMC
80
China Universal Asset Management Company
China
$126K +$56.7K +7,459 +66%
Simplex Trading
81
Simplex Trading
Illinois
$124K +$140K +18,429 New
Arrowstreet Capital
82
Arrowstreet Capital
Massachusetts
$120K +$135K +17,821 New
LCM
83
Landscape Capital Management
New Jersey
$118K -$254K -33,499 -66%
ACM
84
ADAR1 Capital Management
Texas
$101K +$60.9K +8,021 +115%
Citigroup
85
Citigroup
New York
$89.5K +$51.3K +6,756 +104%
SPA
86
Sherbrooke Park Advisers
New York
$80.4K +$90.5K +11,915 New
VEA
87
Virtus ETF Advisers
New York
$80.3K -$6.2K -816 -6%
RJA
88
Raymond James & Associates
Florida
$76.7K +$6.4K +842 +8%
EC
89
EntryPoint Capital
New York
$74.5K -$75.5K -9,935 -47%
Verition Fund Management
90
Verition Fund Management
Connecticut
$73.2K +$82.4K +10,849 New
California State Teachers Retirement System (CalSTRS)
91
California State Teachers Retirement System (CalSTRS)
California
$49.3K -$117K -15,445 -68%
AIP
92
Ameritas Investment Partners
Nebraska
$48.9K +$29.8K +3,921 +118%
Legal & General Group
93
Legal & General Group
United Kingdom
$44.9K -$182K -23,985 -78%
Belvedere Trading
94
Belvedere Trading
Illinois
$38.7K +$43.5K +5,731 New
US Bancorp
95
US Bancorp
Minnesota
$35.6K +$40.1K +5,277 New
MLICM
96
Metropolitan Life Insurance Company (MetLife)
New York
$26.5K +$14.6K +1,927 +96%
Royal Bank of Canada
97
Royal Bank of Canada
Ontario, Canada
$24K -$53.6K -7,061 -66%
QL
98
Quarry LP
New York
$20.3K +$22.8K +3,000 New
AB
99
Amalgamated Bank
New York
$17K -$11K -1,447 -37%
CG
100
Cutler Group
California
$15K -$44.9K -5,906 -72%

SLRN Hedge Fund Activity: Q1 2024 in Review

109 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q1 2024, worth a combined $613M — down 4.1% from $639M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of SLRN and 25 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 46 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $30.5M. The largest seller was Opaleye Management, cutting an estimated $19.5M.

  • 109 institutional investors held ACELYRIN (SLRN) as of Q1 2024, down from 110 in Q4 2023.
  • Funds reported $613M of ACELYRIN stock for Q1 2024, down 4.1% quarter-over-quarter.
  • 25 funds opened new ACELYRIN positions in Q1 2024 and 26 closed out, a net change of -1 holder.
  • The largest ACELYRIN buyer in Q1 2024 was Millennium Management, an estimated $30.5M added.
  • The largest ACELYRIN seller in Q1 2024 was Opaleye Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q1 2024.